Equities researchers at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Intellia ...

Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Intellia Therapeutics in a research report issued to clients and investors on Thursday, February 27th. Leerink ...

Truist analyst Joon Lee lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $90 and keeps a Buy rating on the shares.

NEW YORK, NY / ACCESS Newswire / March 3, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to ...

The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. . Shareholders who purchased shares ...

Intellia Therapeutics’ stock faces risks from market uncertainty and funding needs. Read why NTLA stock is downgraded to HOLD ...

One year after its initial public offering, Helix Acquisition Corp. II is now helping another biotech company go public.

Full Year 2024 Results Key Financial Results Revenue: US$57.9m (up 60% from ...

Fintel reports that on February 28, 2025, JP Morgan downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from ...

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short ...

Intellia Therapeutics Inc (NTLA) reports robust pipeline progress and financial stability, despite increased R&D expenses and ...

John Leonard; President, Chief Executive Officer, Director; Intellia Therapeutics Inc David Lebwohl; Executive Vice President, Chief Medical Officer; Intellia Therapeutics Inc Edward Dulac; Executive ...